Showing results (41-50 of 86) with videos related to
Sort By:
Pageof 9
Leukemia & Lymphoma|July 19, 2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomideDana E Rollison, Rami Komrokji, Ji-Hyun Lee, et al.Frontiers in Oncology|November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary diseaseZiad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.Bioinformatics (Oxford, England)|June 25, 2022
CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimationQibing Jiang, Praneeth Sudalagunta, Maria C Silva, et al.Blood|December 6, 2017
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemiaChristine Chen, David Siegel, Martin Gutierrez, et al.American Journal of Hematology|November 26, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myelomaAleksandr Lazaryan, Mohamad A Hussein, Frederic J Reu, et al.British Journal of Haematology|June 26, 2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myelomaPaul G Richardson, Craig C Hofmeister, Cara A Rosenbaum, et al.Journal of Geriatric Oncology|September 18, 2023
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysisOthman Salim Akhtar, Ba Aqeel Sheeba, Farhan Azad, et al.Current Problems in Cancer|August 29, 2021
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk featuresKwai Han Yoo, Dok Hyun Yoon, Hye Jin Kang, et al.Pageof 9